Vorolanib

EyePoint Pharmaceuticals initiated the LUCIA trial, its second global Phase 3 study of Duravyu for wet AMD. Duravyu, a sustained-release therapy delivering vorolanib via a bioerodible Durasert E formulation, aims to offer long-term management of wet AMD. The LUCIA trial includes treatment-naïve and previously treated patients, with re-dosing every 6 months. The LUGANO and LUCIA trials, comparing Duravyu to aflibercept, aim to enroll 400 patients each worldwide, assessing efficacy, safety, and dosing flexibility.

First patient dosed in phase 3 LUCIA trial of Duravyu for wet AMD, following the phase 3 LUGANO trial. Both trials aim to assess Duravyu's safety and efficacy compared to aflibercept, with Duravyu dosed every 6 months.

EyePoint Pharmaceuticals initiates LUCIA trial, its second global Phase 3 study of Duravyu for wet AMD, featuring a sustained-release therapy with vorolanib delivered via Durasert E. The trial aims to assess efficacy, safety, and dosing flexibility, with re-dosing every 6 months, targeting both treatment-naïve and previously treated patients.

EyePoint Pharmaceuticals announces first patient dosed in LUCIA trial, its second global Phase 3 clinical trial of DURAVYU for wet AMD. DURAVYU, a sustained delivery therapy, aims to improve treatment for serious retinal diseases. The trial is part of a robust clinical dataset for long-acting treatments in wet AMD, positioning EyePoint as a leader in sustained-release ocular drug delivery.

EyePoint Pharmaceuticals granted 23,600 stock options to four new employees on Nov 15, 2024, as inducement awards outside the 2023 LTIP, per NASDAQ Rule 5635(c)(4). The options, priced at $9.17/share, have a 10-year term and vest over four years.

EyePoint Pharmaceuticals' Phase 2 VERONA trial interim data shows Duravyu, a sustained delivery therapy for DME, improved BCVA and CST with a favorable safety profile, outperforming aflibercept control. The company expects full results in Q1 2025.

EyePoint Pharmaceuticals reports positive interim 16-week results from the VERONA trial, showing Duravyu's sustained-release therapy for DME improved BCVA and CST with a favorable safety profile. The 2.7mg dose is also being evaluated for wet AMD, with full results expected in Q1 2025.

DURAVYU 2.7mg showed early, sustained improvement in BCVA (+8.9 letters) and CST (68 microns reduction) in DME patients, with a favorable safety profile. Full topline data expected Q1 2025.

EyePoint Pharmaceuticals initiated the phase 3 LUGANO trial of Duravyu for wet AMD, with plans to start the LUCIA trial by year-end. Both trials will enroll 400 patients, comparing Duravyu to aflibercept, aiming to maintain visual acuity and reduce treatment burden.

Dr. David A. Eichenbaum presented interim PRISM Phase 1/2 trial results on intravitreal 4D-150 for neovascular AMD, showing safety, reduced anti-VEGF injection burden, and stable visual acuity. He also discussed 12-month DAVIO 2 trial results comparing EYP-1901 (vorolanib intravitreal insert) with aflibercept, demonstrating stable visual acuity, strong anatomic control, and reduced treatment burden. Both studies aim to reduce injection frequency in wet AMD treatment.